NM_016239.4:c.9861C>T

Variant summary

Our verdict is Likely pathogenic. Variant got 8 ACMG points: 10P and 2B. PM2PP5_Very_StrongBP4BP7

The NM_016239.4(MYO15A):​c.9861C>T​(p.Gly3287Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000886 in 1,613,930 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).

Frequency

Genomes: 𝑓 0.00011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000087 ( 0 hom. )

Consequence

MYO15A
NM_016239.4 synonymous

Scores

2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:7

Conservation

PhyloP100: -1.25
Variant links:
Genes affected
MYO15A (HGNC:7594): (myosin XVA) This gene encodes an unconventional myosin. This protein differs from other myosins in that it has a long N-terminal extension preceding the conserved motor domain. Studies in mice suggest that this protein is necessary for actin organization in the hair cells of the cochlea. Mutations in this gene have been associated with profound, congenital, neurosensory, nonsyndromal deafness. This gene is located within the Smith-Magenis syndrome region on chromosome 17. Read-through transcripts containing an upstream gene and this gene have been identified, but they are not thought to encode a fusion protein. Several alternatively spliced transcript variants have been described, but their full length sequences have not been determined. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 8 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-18166434-C-T is Pathogenic according to our data. Variant chr17-18166434-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 45777.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.54). . Strength limited to SUPPORTING due to the PP5.
BP7
Synonymous conserved (PhyloP=-1.25 with no splicing effect.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MYO15ANM_016239.4 linkc.9861C>T p.Gly3287Gly synonymous_variant Exon 61 of 66 ENST00000647165.2 NP_057323.3 Q9UKN7-1
MYO15AXM_017024715.3 linkc.9864C>T p.Gly3288Gly synonymous_variant Exon 59 of 64 XP_016880204.1
MYO15AXM_017024714.3 linkc.9801C>T p.Gly3267Gly synonymous_variant Exon 58 of 63 XP_016880203.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MYO15AENST00000647165.2 linkc.9861C>T p.Gly3287Gly synonymous_variant Exon 61 of 66 NM_016239.4 ENSP00000495481.1 Q9UKN7-1

Frequencies

GnomAD3 genomes
AF:
0.000105
AC:
16
AN:
152202
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00403
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000188
AC:
47
AN:
249412
Hom.:
0
AF XY:
0.000177
AC XY:
24
AN XY:
135320
show subpopulations
Gnomad AFR exome
AF:
0.0000646
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00407
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000177
Gnomad OTH exome
AF:
0.000495
GnomAD4 exome
AF:
0.0000869
AC:
127
AN:
1461728
Hom.:
0
Cov.:
33
AF XY:
0.0000921
AC XY:
67
AN XY:
727166
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00329
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000216
Gnomad4 OTH exome
AF:
0.000215
GnomAD4 genome
AF:
0.000105
AC:
16
AN:
152202
Hom.:
0
Cov.:
32
AF XY:
0.0000403
AC XY:
3
AN XY:
74358
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00403
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000294
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000316
Hom.:
0
Bravo
AF:
0.0000982
EpiCase
AF:
0.000164
EpiControl
AF:
0.000119

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:3
Aug 01, 2023
GeneDx
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Published functional studies suggest that this variant results in aberrant splicing and "skipping" of exon 61 (Hirsch et al., 2021); This variant is associated with the following publications: (PMID: 33398081, WangS2023[casereport], 33111345, 34733312) -

Oct 22, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change affects codon 3287 of the MYO15A mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the MYO15A protein. This variant is present in population databases (rs372466080, gnomAD 0.4%). This variant has been observed in individual(s) with non-syndromic deafness (PMID: 33111345, 33398081, 34733312). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It is commonly reported in individuals of Ashkenazi Jewish ancestry (PMID: 33111345, 33398081, 34733312). ClinVar contains an entry for this variant (Variation ID: 45777). Studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 33398081). For these reasons, this variant has been classified as Pathogenic. -

Feb 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

MYO15A: PM3:Very Strong, PM2:Supporting, PS3:Supporting, BP4 -

Autosomal recessive nonsyndromic hearing loss 3 Pathogenic:2
Feb 13, 2025
Illumina Laboratory Services, Illumina
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Laboratory of Prof. Karen Avraham, Tel Aviv University
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

The MYO15A c.9861C>T:p.G3287G variant has been detected in our study, in 2 Jewish Ashkenazi families, in compound heterozygosity with another known Ashkenazi MYO15A mutation: c.8183G>A:p.R2728H. Following immediate application of our findings in the genetics clinics in Israel, 5 additional families were detected with full segregation of this variant in compound heterozygosity with a known MYO15A deafness variant. Compound heterozygosity has not been detected in none if the 23 hearing members in these families. MYO15A c.9861C>T is predicted to lead to loss of splicing enhancer motifs by 4 of 6 HSF algorithms and to lead to gain of silencer motifs by 2 of 6 algorithms. Skipping of MYO16A exon 61 would lead to a message deletion of 161bp and a premature stop at codon 3266 of 3531. -

MYO15A-related disorder Pathogenic:1
Nov 29, 2022
PreventionGenetics, part of Exact Sciences
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The MYO15A c.9861C>T variant is not predicted to result in an amino acid change (p.=). This variant has been reported in the homozygous and compound heterozygous states in patients with nonsyndromic hearing loss (Brownstein et al 2020. PubMed ID: 33111345; Hirsch et al 2021. PubMed ID: 33398081; Booth et al 2021. PubMed ID: 34733312). Functional in vitro studies have shown this variant results in exon skipping, a frameshift and premature termination (Hirsch et al 2021. PubMed ID: 33398081). This variant is reported in 0.41% of alleles in individuals of Ashkenazi Jewish descent in gnomAD and has been described as a pathogenic founder variant in this population (http://gnomad.broadinstitute.org/variant/17-18069748-C-T; Brownstein et al 2020. PubMed ID: 33111345). This variant is interpreted as likely pathogenic. -

Rare genetic deafness Pathogenic:1
Oct 22, 2020
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

proposed classification - variant undergoing re-assessment, contact laboratory -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.54
CADD
Benign
0.93
DANN
Benign
0.64

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs372466080; hg19: chr17-18069748; API